SGC-dominant PKC-α-MAPK14-ADAM17 signaling emerges as a therapeutic hub to mitigate neuronal remodeling and cardiac sympathetic overactivation in T2DM. This evidence concerns the gene ADAM17 and type 2 diabetes mellitus.